Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes
Archives of Gynecology and Obstetrics · 2025
DOI: 10.1007/s00404-025-08174-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Gynecology and Obstetrics, 2025. Verfasst von Brooke Vandermolen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. Brooke.vandermolen@nhs.net. Hauptthemen laut MEDLINE: Uterine Myomectomy, Leiomyoma, Uterine Neoplasms, Norethindrone. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
INTRODUCTION: Gonadotropin-releasing hormone (GnRH) receptor antagonists in combination therapy offer a promising advancement in the medical management of uterine fibroids. While effective for symptom control, limited data exist on their impact on surgical outcomes, particularly during laparoscopic myomectomy. This case series describes the surgical findings in three patients who received preoperative Relugolix combination therapy (Relugolix-CT: relugolix-estradiol-norethisterone acetate) compared to no pretreatment. MATERIALS AND METHODS: We conducted a retrospective review of 24 patients who underwent laparoscopic myomectomy over a 6-month period. Three patients received a preoperative course of Relugolix-CT for 3, 6, and 9 months, respectively, while 21 patients underwent surgery without pretreatment. RESULTS: Blood loss was lower in the Relugolix-CT group (216.6 mL ± 189.7) vs. the no-pretreatment group (354.8 mL ± 131.9. Operating time was similar (148.3 vs. 148.1 min), as was duration of inpatient stay (1.3 vs. 2.0 days). No complications occurred in either group. Notably, in all cases with Relugolix-CT pretreatment, no distortion or fibrosis of the fibroid pseudocapsule was noted, allowing for complete resection of the fibroids. CONCLUSIONS: This case series suggests that preoperative Relugolix-CT does not adversely affect surgical planes or operative outcomes. Although preliminary, these findings suggest benefits for surgical optimisation and support further investigation in larger, controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Whipps Cross University Hospital, Barts Health NHS Trust, London, UK. Brooke.vandermolen@nhs.net.
- Whipps Cross University Hospital, Barts Health NHS Trust, London, UK.
Zitieren
APA
Vandermolen, B., Reindorf, M., McMurray, R., Aref-Adib, M., & Odejinmi, F. (2025). Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-025-08174-5
Vancouver
Vandermolen B, Reindorf M, McMurray R, Aref-Adib M, Odejinmi F. Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes. Archives of Gynecology and Obstetrics. 2025. doi:10.1007/s00404-025-08174-5
BibTeX
@article{Vandermolen2025,
author = {Vandermolen, Brooke and Reindorf, Maxine and McMurray, Rebecca and Aref-Adib, Mehrnoosh and Odejinmi, Funlayo},
title = {Preoperative relugolix combination therapy in laparoscopic myomectomy: a case series evaluating impact on surgical planes and operative outcomes},
journal = {Archives of Gynecology and Obstetrics},
year = {2025},
doi = {10.1007/s00404-025-08174-5}
}
EUVIMED